AIQ’s TRAQinform software technology quantifies and classifies lesion-specific treatment response and organ-specific toxicity from longitudinal imaging scans. It can deliver an early prediction of optimal/suboptimal responders to therapies, allowing for informed patient selection and efficient go/no-go clinical decisions. It can also provide concordance between multiple imaging modalities and radiotracers. The technology is AI-driven and some features have been cleared by the FDA for use in patient care under the product name TRAQinform IQ.